Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacokinetics and Pharmacodynamics of Pimobendan-Pentoxifylline Liquid Mixture After Oral Administration in Dogs

  • Ro, Woong-bin (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Song, Doo-won (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Kim, Ki-hun (Biomedical Science Research Institute, Hoseo University) ;
  • Jeong, Sang-hee (Biomedical Science Research Institute, Hoseo University) ;
  • Kang, Min-hee (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
  • Received : 2019.02.24
  • Accepted : 2019.03.13
  • Published : 2019.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Pimobendan is an inodilator used to treat canine heart failure, and pentoxifylline is reported to be beneficial for microcirculation and heart disease. The purpose of this study was to evaluate the pharmacokinetic and pharmacodynamic profiles of a novel pimobendan-pentoxifylline liquid mixture after oral administration to dogs. Eight healthy Beagle dogs were included in the study. The dogs were divided into the control group (orally administered water; n = 4) and experimental group (orally administered pimobendan-pentoxifylline liquid mixture [pimobendan 0.25 mg/kg, pentoxifylline 15 mg/kg]; n = 4). Plasma samples were obtained and echocardiographic indices were measured for 24 hours after administration. The concentrations of pimobendan and pentoxifylline were quantified by using a liquid chromatography-mass spectrometer (LC-MS). The elimination half-life ($T_{1/2}$) was $32.96{\pm}9.80mins$ for pimobendan and $29.49{\pm}6.67mins$ for pentoxifylline. The time to reach maximum concentration ($T_{max}$) were $52.50{\pm}31.22mins$ for pimobendan and $41.25{\pm}18.87mins$ for pentoxifylline. The maximum blood concentration ($C_{max}$) was $96.92{\pm}75.64ng/mL$ for pimobendan and $7074.07{\pm}3261.1ng/mL$ for pentoxifylline. Of the echocardiographic indices, fractional shortening (FS) and left ventricular internal diameter at end systole (LVIDs) were significantly altered at 1-3 hours after the administration of pimobendan-pentoxifylline liquid mixture. The pimobendan-pentoxifylline liquid mixture was well tolerated by the dogs, with no adverse effects observed during the study.

Keywords

References

  1. Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, Hamlin R, Keene B, Luis-Fuentes V, Stepien R. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23: 1142-1150. https://doi.org/10.1111/j.1939-1676.2009.0392.x
  2. Bell E, Devi J, Chiu S, Zahra P, Whittem T. The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs. J Vet Pharmacol Ther 2016; 39: 54-61. https://doi.org/10.1111/jvp.12235
  3. Boehringer Ingelheim. Clinical pharmacology. In: Vetmedin Detail Sheet. Ingelheim am Rhein, Germany: Boehringer Ingelheim. 2007: 2.
  4. Cornell CC, Kittleson MD, Torre PD, Haggstrom J, Lombard CW, Pedersen HD, Vollmar A, Wey A. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004; 18: 311-321. https://doi.org/10.1111/j.1939-1676.2004.tb02551.x
  5. Haggstrom J, Boswood A, O'Grady M, Jons O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacevic A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Ronn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 2008; 22: 1124-1135. https://doi.org/10.1111/j.1939-1676.2008.0150.x
  6. Kanno N, Kuse H, Kawasaki M, Hara A, Kano R, Sasaki Y. Effects of pimobendan for mitral valve regurgitation in dogs. J Vet Med Sci 2007; 69: 373-377. https://doi.org/10.1292/jvms.69.373
  7. Marsella R, Nicklin CF, Munson JW, Roberts SM. Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration. Am J Vet Res 2000; 61: 631-637. https://doi.org/10.2460/ajvr.2000.61.631
  8. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-97. https://doi.org/10.2165/00003495-198734010-00003
  9. Watanabe H, Furukawa Y, Chiba S. Cardiovascular effects of aminophylline and pentoxifylline on intact dogs and isolated dog atria. Jpn Heart J 1982; 23: 235-243. https://doi.org/10.1536/ihj.23.235
  10. Yata M, McLachlan A, Foster D, Page S, Beijerink N. Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs. J Vet Pharmacol Ther 2016; 39: 45-53. https://doi.org/10.1111/jvp.12243
  11. Zhang M, Xu YJ, Mengi SA, Arneja AS, Dhalla NS. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol 2004; 9: 103.